Pharmaceutical Technology's In the Lab eNewsletter
Cell DIVE is a new cell imaging technology from GE Healthcare that allows for more precise biomarker analysis.
Cell DIVE is the latest tech offering from GE Healthcare, which launched the cell imaging system in late September 2019. Cell DIVE multiplexed imaging is an antibody-based system that allows for more precise biomarker analysis.
The technology was developed by scientists for scientists, GE Healthcare stated. The seminal work started in 2008 and the first patent was issued in 2009. Over the last decade, Cell DIVE has been evaluated globally through multiple collaborators resulting in a library of publications, presentations, and research.
At its core, scientists will iteratively probe, image, and de-stain to capture thousands of spatial cellular data points from just one tissue image. With an extensive list of validated antibodies in GE Healthcare’s library, scientists can customize their own panels and have the flexibility to stain and image as they need. Tissue sample would not be harmed with the gentle protocol used by the system, such as no stripping of antibodies or complicated sample prep required.
“Cell DIVE multiplexed imaging is another example of our commitment to furthering access to life-changing biotherapeutics and diagnostics,” said Emmanuel Abate, general manager Genomics and Cellular Research, GE Healthcare Life Sciences, in a Sept. 26, 2019 company press release. “These are exciting days in immuno-oncology and we are early in our understanding in how a patient’s biomarker profile contributes to a therapeutic outcome.”
“The flexibility of an open system that allows for custom biomarker panel design moves us closer to a definitive diagnostic tool,” said Prachi Bogetto, Diagnostics Segment leader, GE Healthcare Life Sciences, in the press release. “This flexible solution also supports whole slide, region of interest, and tissue microarray (TMA) imaging.”
Source: GE Healthcare
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.